No Data
While Shareholders of Ascendis Pharma (NASDAQ:ASND) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $191
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $174
Express News | Ascendis Pharma A/S : JP Morgan Cuts Target Price to $174 From $180